{"doi":"10.1111/dom.12253","title":"Lixisenatide, a novel <scp>GLP</scp>‐1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus","abstract":"<jats:p>Recent advances in therapies for the treatment of type 2 diabetes mellitus (<jats:styled-content style=\"fixed-case\">T2DM</jats:styled-content>) have led to the development of glucagon‐like peptide‐1 receptor agonists (<jats:styled-content style=\"fixed-case\">GLP</jats:styled-content>‐1 <jats:styled-content style=\"fixed-case\">RAs</jats:styled-content>), which, unlike insulin and sulphonylurea, are effective, with a low risk of hypoglycaemia. Lixisenatide is recommended as a once‐daily <jats:styled-content style=\"fixed-case\">GLP</jats:styled-content>‐1 <jats:styled-content style=\"fixed-case\">RA</jats:styled-content> for the treatment of <jats:styled-content style=\"fixed-case\">T2DM</jats:styled-content>. In persons with <jats:styled-content style=\"fixed-case\">T2DM</jats:styled-content>, lixisenatide 20 µg once‐daily given by bolus subcutaneous injection improves insulin secretion and suppresses glucagon secretion in a glucose‐dependent manner. Compared with the longer‐acting <jats:styled-content style=\"fixed-case\">GLP</jats:styled-content>‐1 <jats:styled-content style=\"fixed-case\">RA</jats:styled-content> liraglutide, lixisenatide achieved a significantly greater reduction in postprandial plasma glucose (<jats:styled-content style=\"fixed-case\">PPG</jats:styled-content>) during a standardized test breakfast in persons with <jats:styled-content style=\"fixed-case\">T2DM</jats:styled-content> otherwise insufficiently controlled on metformin alone. This is primarily due to the greater inhibition of gastric motility by lixisenatide compared with liraglutide. The efficacy and safety of lixisenatide was evaluated across a spectrum of <jats:styled-content style=\"fixed-case\">T2DM</jats:styled-content> in a series of phase <jats:styled-content style=\"fixed-case\">III</jats:styled-content>, randomized, placebo‐controlled trials known as the <jats:styled-content style=\"fixed-case\">GetGoal</jats:styled-content> programme. Lixisenatide monotherapy or as add‐on to oral antidiabetic agents or basal insulin achieved significant reductions in glycated haemoglobin, <jats:styled-content style=\"fixed-case\">PPG</jats:styled-content> and fasting plasma glucose, with either weight loss or no weight gain. The most frequent adverse events were gastrointestinal and transient in nature. Lixisenatide provides an easy, once‐daily, single‐dose, add‐on treatment to oral antidiabetic agents or basal insulin for the management of <jats:styled-content style=\"fixed-case\">T2DM</jats:styled-content>, with little or no increased risk of hypoglycaemia and a potential beneficial effect on body weight.</jats:p>","journal":"Diabetes, Obesity and Metabolism","year":2014,"id":627759,"datarank":0.5416376868966337,"base_score":3.6109179126442243,"endowment":3.6109179126442243,"self_citation_contribution":0.5416376868966337,"citation_network_contribution":0.0,"self_endowment_contribution":0.5416376868966337,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":36,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1624968,"name":"D. R. Owens","orcid":null,"position":1,"is_corresponding":false},{"id":1624967,"name":"G. B. Bolli","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Lixisenatide, a novel <scp>GLP</scp>‐1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus","abstract":"<jats:p>Recent advances in therapies for the treatment of type 2 diabetes mellitus (<jats:styled-content style=\"fixed-case\">T2DM</jats:styled-content>) have led to the development of glucagon‐like peptide‐1 receptor agonists (<jats:styled-content style=\"fixed-case\">GLP</jats:styled-content>‐1 <jats:styled-content style=\"fixed-case\">RAs</jats:styled-content>), which, unlike insulin and sulphonylurea, are effective, with a low risk of hypoglycaemia. Lixisenatide is recommended as a once‐daily <jats:styled-content style=\"fixed-case\">GLP</jats:styled-content>‐1 <jats:styled-content style=\"fixed-case\">RA</jats:styled-content> for the treatment of <jats:styled-content style=\"fixed-case\">T2DM</jats:styled-content>. In persons with <jats:styled-content style=\"fixed-case\">T2DM</jats:styled-content>, lixisenatide 20 µg once‐daily given by bolus subcutaneous injection improves insulin secretion and suppresses glucagon secretion in a glucose‐dependent manner. Compared with the longer‐acting <jats:styled-content style=\"fixed-case\">GLP</jats:styled-content>‐1 <jats:styled-content style=\"fixed-case\">RA</jats:styled-content> liraglutide, lixisenatide achieved a significantly greater reduction in postprandial plasma glucose (<jats:styled-content style=\"fixed-case\">PPG</jats:styled-content>) during a standardized test breakfast in persons with <jats:styled-content style=\"fixed-case\">T2DM</jats:styled-content> otherwise insufficiently controlled on metformin alone. This is primarily due to the greater inhibition of gastric motility by lixisenatide compared with liraglutide. The efficacy and safety of lixisenatide was evaluated across a spectrum of <jats:styled-content style=\"fixed-case\">T2DM</jats:styled-content> in a series of phase <jats:styled-content style=\"fixed-case\">III</jats:styled-content>, randomized, placebo‐controlled trials known as the <jats:styled-content style=\"fixed-case\">GetGoal</jats:styled-content> programme. Lixisenatide monotherapy or as add‐on to oral antidiabetic agents or basal insulin achieved significant reductions in glycated haemoglobin, <jats:styled-content style=\"fixed-case\">PPG</jats:styled-content> and fasting plasma glucose, with either weight loss or no weight gain. The most frequent adverse events were gastrointestinal and transient in nature. Lixisenatide provides an easy, once‐daily, single‐dose, add‐on treatment to oral antidiabetic agents or basal insulin for the management of <jats:styled-content style=\"fixed-case\">T2DM</jats:styled-content>, with little or no increased risk of hypoglycaemia and a potential beneficial effect on body weight.</jats:p>","is_dataset_classified":null,"base_score":3.6109179126442243,"endowment":3.6109179126442243,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"24373190","pmcid":null,"openalex_id":"https://openalex.org/W1978569902","authors":[],"funders":[],"total_grants":0,"fwci":2.3762,"citation_percentile":0.88886453,"influential_citations":0,"citation_trend":[{"year":2014,"count":5},{"year":2015,"count":4},{"year":2016,"count":4},{"year":2017,"count":1},{"year":2018,"count":4},{"year":2019,"count":3},{"year":2020,"count":3},{"year":2021,"count":4},{"year":2023,"count":3},{"year":2024,"count":3},{"year":2025,"count":2}],"oa_status":"closed","license":"http://onlinelibrary.wiley.com/termsAndConditions#vor","oa_locations":[{"url":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fdom.12253","host_type":"publisher"},{"url":"https://dom-pubs.pericles-prod.literatumonline.com/doi/pdf/10.1111/dom.12253","host_type":"publisher"},{"url":"https://doi.org/10.1111/dom.12253","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/24373190","host_type":"repository"}],"fields_of_study":["Diabetes Treatment and Management","Metabolism, Diabetes, and Cancer","Diabetes Management and Research","Blood Glucose","Clinical Trials, Phase III as Topic","Diabetes Mellitus, Type 2","Drug Administration Schedule","Glucagon-Like Peptide-1 Receptor","Glycated Hemoglobin","Humans","Hypoglycemic Agents","Insulin","Insulin Secretion","Metformin","Peptides","Randomized Controlled Trials as Topic","Receptors, Glucagon","Treatment Outcome","Glucagon-Like Peptide-2 Receptor"],"mesh_terms":["Glucagon-Like Peptide-1 Receptor","Glucagon-Like Peptide-2 Receptor","Insulin Secretion","Blood Glucose","Diabetes Mellitus, Type 2","Drug Administration Schedule","Glycated Hemoglobin","Humans","Hypoglycemic Agents","Insulin","Metformin","Peptides","Randomized Controlled Trials as Topic","Treatment Outcome","Clinical Trials, Phase III as Topic","Receptors, Glucagon"],"keywords":["Lixisenatide","Medicine","Liraglutide","Metformin","Postprandial","Internal medicine","Type 2 Diabetes Mellitus","Endocrinology","Type 2 diabetes","Glucagon-like peptide 1 receptor","Diabetes mellitus","Gastric emptying","Hypoglycemia","Adverse effect","Insulin","Pharmacology","Agonist","Receptor","Stomach","Glp-1"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-04T18:48:36.559438Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}